TSE:VRX - Valeant Pharmaceuticals International Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: C$0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
C$30.80
▼ -1.06 (-3.33%)

This chart shows the closing price for VRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Valeant Pharmaceuticals International Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VRX

Analyst Price Target is C$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Valeant Pharmaceuticals International in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a -100.00% upside from the last price of C$30.80.

This chart shows the closing price for VRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Valeant Pharmaceuticals International. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/16/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/16/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/15/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/27/2018Royal Bank of CanadaBoost Price TargetSector PerformC$19.00 ➝ C$25.00
11/8/2017Royal Bank of CanadaReiterated RatingSector PerformC$23.00
11/8/2017TD SecuritiesUpgradeHold ➝ BuyC$25.50
10/20/2017Royal Bank of CanadaLower Price TargetSector PerformC$22.50
(Data available from 8/16/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/18/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/17/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/19/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/18/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/18/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/17/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/17/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/16/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Valeant Pharmaceuticals International logo
Valeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The Bausch + Lomb/International segment provides pharmaceutical products, OTC products, and medical device products, primarily consist of Bausch + Lomb products, with a focus on the vision care, surgical, consumer, and ophthalmology Rx products in the United States; and pharmaceutical products, generic pharmaceutical products, OTC products, medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia and New Zealand, Latin America, Africa, and the Middle East. The Branded Rx segment sells gastrointestinal and dermatological products in the United States. The U.S. Diversified Products segment offers pharmaceutical products, OTC products, and medical device products in the areas of neurology and certain other therapeutic classes, including aesthetics. The company was founded in 1983 and is headquartered in Laval, Canada.
Read More

Today's Range

Now: C$30.80
Low: C$30.75
High: C$32.19

50 Day Range

MA: C$30.80
Low: C$30.80
High: C$30.80

52 Week Range

Now: C$30.80
Low: C$14.01
High: C$36.02

Volume

1,232,408 shs

Average Volume

1,382,994 shs

Market Capitalization

C$10.76 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Valeant Pharmaceuticals International?

The following equities research analysts have issued reports on Valeant Pharmaceuticals International in the last twelve months:
View the latest analyst ratings for VRX.

What is the current price target for Valeant Pharmaceuticals International?

0 Wall Street analysts have set twelve-month price targets for Valeant Pharmaceuticals International in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for Valeant Pharmaceuticals International in the next year.
View the latest price targets for VRX.

What is the current consensus analyst rating for Valeant Pharmaceuticals International?

Valeant Pharmaceuticals International currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for VRX.

What other companies compete with Valeant Pharmaceuticals International?

How do I contact Valeant Pharmaceuticals International's investor relations team?

Valeant Pharmaceuticals International's physical mailing address is 2150 Saint-Elzear Blvd W, LAVAL, QC H7L 4A8, Canada. The specialty pharmaceutical company's listed phone number is +1-514-7446792. The official website for Valeant Pharmaceuticals International is www.valeant.com. Learn More about contacing Valeant Pharmaceuticals International investor relations.